close 74% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Dashboard
Kodu・Aktsiate loetelu・Roche Holding AG
Search

Roche Holding AG

Avatud

SektorTervishoid

279.2 0.22

Hinna uuendus 25. apr 2025, 14:53 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

273.4

Max

280

Põhinäitajad

By Trading Economics

Sissetulek

6.3B

Müük

31B

P/E

Sektori keskmine

26.169

57.333

Dividenditootlus

3.6

Kasumimarginaal

20.347

Töötajad

103,249

EBITDA

11B

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.60%

2.63%

Turustatistika

By TradingEconomics

Turukapital

205B

Eelmine avamishind

278.98

Eelmine sulgemishind

279.2

Roche Holding AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 07:30 UTC

Tulu

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push -- Update

DJ

Loe

24. apr 2025, 05:31 UTC

Tulu

Roche Sales Rise Boosted By Key Drugs

DJ

Loe

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

DJ

Loe

12. märts 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

DJ

Loe

30. jaan 2025, 09:36 UTC

Tulu

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

DJ

Loe

30. jaan 2025, 06:32 UTC

Tulu

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

DJ

Loe

24. apr 2025, 09:39 UTC

Market Talk
Tulu

Roche's Pipeline in Focus After Solid Results -- Market Talk

DJ

Loe

24. apr 2025, 09:24 UTC

Market Talk
Tulu

Roche's Reiterated Outlook Looks Reassuring -- Market Talk

DJ

Loe

24. apr 2025, 09:18 UTC

Market Talk
Tulu

Roche's Results Are Solid -- Market Talk

DJ

Loe

24. apr 2025, 05:16 UTC

Peamised uudised

Roche Sales Rise, Boosted By Key Drugs

DJ

Loe

22. apr 2025, 10:51 UTC

Peamised uudised

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

DJ

Loe

15. apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

DJ

Loe

9. apr 2025, 10:03 UTC

Market Talk
Tulu

Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk

DJ

Loe

9. apr 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

DJ

Loe

3. apr 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

DJ

Loe

3. apr 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

DJ

Loe

31. märts 2025, 09:31 UTC

Kuumad aktsiad

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

DJ

Loe

13. märts 2025, 07:46 UTC

Market Talk

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

DJ

Loe

12. märts 2025, 16:34 UTC

Peamised uudised

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

DJ

Loe

12. märts 2025, 08:51 UTC

Market Talk

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

DJ

Loe

12. märts 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

DJ

Loe

13. veebr 2025, 11:43 UTC

Market Talk

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

DJ

Loe

30. jaan 2025, 07:56 UTC

Market Talk
Tulu

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

DJ

Loe

30. jaan 2025, 06:04 UTC

Tulu

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

DJ

Loe

30. jaan 2025, 06:04 UTC

Tulu

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

DJ

Loe

30. jaan 2025, 06:04 UTC

Tulu

Roche Issues 2025 View

DJ

Loe

30. jaan 2025, 06:03 UTC

Tulu

Roche Raises Dividend to CHF9.70 Vs CHF9.60

DJ

Loe

30. jaan 2025, 06:03 UTC

Tulu

Roche 2024 Core Operating Profit CHF20.82B

DJ

Loe

30. jaan 2025, 06:03 UTC

Tulu

Roche 2024 Net Pft CHF9.19B

DJ

Loe

30. jaan 2025, 06:02 UTC

Tulu

Analysts Saw 2024 Core EPS at CHF18.59

DJ

Loe

Roche Holding AG Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.